NCT03315455View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

August 3, 2022

Study Completion Date

August 29, 2025

Conditions
Hemophilia A
Interventions
DRUG

Emicizumab

Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.

Trial Locations (12)

10400

Ramathibodi Hospital, Bangkok

10990

Penang General Hospital, George Town

88586

Queen Elizabeth Hospital, Sabah

100730

Peking Union Medical College Hospital, Beijing

200025

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

300020

Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin

410008

Xiangya Hospital of Centre-South University, Changsha

430022

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology, Wuhan

430030

Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan

510515

Southern Medical University Nanfang Hospital, Guangdong Province Guangzhou City

Unknown

Queen Mary Hospital, Hong Kong

Prince of Wales Hospital, Shatin

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03315455 - Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants | Biotech Hunter | Biotech Hunter